|Table of Contents|

Significiance of CrkL phosphorylation analysis by flow cytometry in imatinib treated chronic myelogenous leukemia

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2015 05
Page:
614-617
Research Field:
Publishing date:

Info

Title:
Significiance of CrkL phosphorylation analysis by flow cytometry in imatinib treated chronic myelogenous leukemia
Author(s):
Su Nan; Wang Pingping; Qu Yi; Li Yan
Hematology Department，the First Affiliated Hospital of China Medical University，Liaoning Shenyang 110001，China.
Keywords:
flow cytometry; chronic myelogenous leukemia; imatinib; CrkL phosphorylation
PACS:
R733.72
DOI:
10.3969/j.issn.1672-4992.2015.05.10
Abstract:
Objective：To detect the level of p-CrkL and bcr-abl fusion gene expression in chronic myelogenous leukemia patients before and after imatinib treated by flow cytometry (FCM） and fluorescence quantitative PCR,to explore the clinical significiance of p-CrkL analysis by FCM.Methods：We detected the level of p-CrkL of K562 cell after imatinib processed and expressed by CD34+ cell in marrow or peripheral blood of 24 CML patients after taking imatinib in different time,to observe the change of p-CrkL before and after treatment.Results：The level of p-CrkL of K562 cell obviously decreased after treated by imatinib,and the level of p-CrkL expressed by CD34+ cell in CML patients obviously decreased.The change trend of p-CrkL by FCM was identicial as that of bcr-abl by fluorescence quantitative PCR.Conclusion：P-CrkL can be used as a alternative marker of bcr-abl as evaluation of imatinib for the treatment of the therapeutic effects of CML signs，detection of p-CrkL by FCM is simple，fast.

References:

[1]Rowley JD.A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining［J］.Nature，1973，243(5405):290-293.
[2]Gonon-Demoulian R，Goldman JM，Nicolini FE.History of chronic myeloid leukemia：a paradigm in the treatment of cancer［J］.Bull Cancer,2014,101(1)：56-67.
[3]Vasconcelos FC,Nestal de Moraes G,Moellmann-Coelho A,et al.Phosphorylated CrkL reduction levels are associated with the lowest P-glycoprotein activity levels in cells from chronic myeloid leukemia patients［J］.Leuk Res,2013,37(12)：1711-1718.
[4]Oda T，Heaney C，Hagopian JR,et al.CrkL is the major tyrosine-phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia［J］.J Biol Chem，1994,269(37)：22925-22928.
[5]Nichols GL，Raines MA，Vera JC,et al.Identification of CrkL as the constitutively phosphorylated 39-kD tyrosine phosphoprotein in chronic myelogenous leukemia cells［J］.Blood,1994,84(9):2912-2918.
[6]ten Hoeve J.Tyrosine phosphorylation of CrkL in Philadelphia+ leukemia［J］.Blood，1994，84(6)：1731-1736.
[7]Hochhaus A，Kreil S，Corbin A,et al.Roots of clinical resistance to STI-571 cancer therapy［J］.Science,2001,293(5538):2163.
[8]White D，Saunders V，Lyons AB,et al.In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML［J］.Blood，2005,106(7)：2520-2526.
[9]Patel H,Marley SB，Gordon MY.Detection in primary chronic myeloid leukaemia cells of p210bcr-abl in complexes with adaptor proteins CBL，CrkL，and GRB2［J］.Genes Chromosomes Cancer,2006,45(12)：1121-1129.
[10]O'Hare T，Pollock R，Stoffregen EP，et al.Inhibition of wild-type and mutant bcr-abl by AP23464，a potent ATP-based oncogenic protein kinase inhibitor：implications for CML［J］.Blood,2004，104(8)：2532-2539.
[11]Gabert J,Beillard E,van der Velden VH，et al.Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia-a Europe Against Cancer program［J］.Leukemia,2003，17(12)：2318-2357.
[12]Wisniewski D,Strife A,Swendeman S,et al.A novel SH2-containing phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase（SHIP2）is constitutively tyrosine phosphorylated and associated with src homologous and collagen gene（SHC）in chronic myelogenous leukemia progenitor cells［J］.Blood,1999,93(8)：2707-2720.
[13]Leung KK，Hause RJ Jr，Barkinge JL,et al.Enhanced prediction of SH2 domain binding potentials using a fluorescence polarization-derived c-Met，c-Kit，ErbB，and androgen receptor interactome［J］.Mol Cell Proteomics,2014，13(7):1705-1723.
[14]Desplat V，Lagarde V，Belloc F,et al.Rapid detection of phosphotyrosine proteins by flow cytometric analysis in bcr-abl-positive cells［J］.Cytometry A，2004,62(1)：35-45.

Memo

Memo:
-
Last Update: 2015-01-30